Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MIRAPEX | Boehringer Ingelheim | N-020667 DISCN | 1997-07-01 | 7 products, RLD |
MIRAPEX ER | Boehringer Ingelheim | N-022421 DISCN | 2010-02-19 | 7 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
mirapex | New Drug Application | 2010-12-29 |
pramipexole | ANDA | 2016-10-13 |
pramipexole dihydrochloride | ANDA | 2025-02-11 |
pramipexole dihydrochloride pramipexole dihydrochloride | ANDA | 2024-07-23 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
parkinson disease | EFO_0002508 | D010300 | G20 |
depressive disorder | EFO_1002014 | D003866 | F32.A |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Pramipexole |
INN | pramipexole |
Description | Pramipexole is a member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively. It has a role as an antiparkinson drug, a dopamine agonist, an antidyskinesia agent and a radical scavenger. It is a member of benzothiazoles and a diamine. It is a conjugate base of a pramipexole(2+). |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCN[C@H]1CCc2nc(N)sc2C1 |
PDB | — |
CAS-ID | 104632-26-0 |
RxCUI | — |
ChEMBL ID | CHEMBL301265 |
ChEBI ID | 8356 |
PubChem CID | 119570 |
DrugBank | DB00413 |
UNII ID | 83619PEU5T (ChemIDplus, GSRS) |